N@N

Targacept to Present at Credit Suisse 2010 Healthcare Conference

^{Published on 2010-11-05 19:01:29 - Market Wire}
 

WINSTON-SALEM, N.C.--([ BUSINESS WIRE ])--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeuticsa", today announced that Alan A. Musso, Senior Vice President, Finance and Administration and Chief Financial Officer, is scheduled to present at the Credit Suisse 2010 Healthcare Conference at the Arizona Biltmore Hotel in Phoenix, Arizona on Friday, November 12, 2010 at 9:30 a.m. Mountain Standard Time.

Mr. Mussoa™s presentation will be webcast and accessible from the Investor Relations page of Targacepta™s website, [ www.targacept.com ]. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Investor Calendar section of the Investor Relations page of Targacepta™s website for at least two weeks following the corresponding event.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeuticsa" for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacept's lead program, TC-5214, is in Phase 3 development as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentada" to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies. For more information, please visit [ www.targacept.com ].

TARGACEPT
Building Health, Restoring Independencea"